STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.53
-$0.12 (-1.80%)
At close: Oct 30, 2026, 3:59 PM ET
$6.53
$0.00 (0.00%)
Pre-market:
Nov 2, 2026, 9:10 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Revenue | 161.28M | 147.44M | 141.96M | 136.56M |
Cost of Revenue | 134.12M | 124.13M | 119.19M | 117.64M |
Gross Profit | 27.17M | 23.32M | 22.77M | 18.92M |
Operating Income | -4.62M | -6.51M | -6.91M | -8.05M |
Interest Income | n/a | n/a | n/a | n/a |
Pretax Income | -9.79M | -2.49M | -7.51M | -16.5M |
Net Income | -9.79M | -2.49M | -7.51M | -16.5M |
Selling & General & Admin | 29.94M | 28.21M | 28.04M | 25.25M |
Research & Development | n/a | n/a | n/a | n/a |
Other Expenses | 1.84M | 1.62M | 1.63M | 1.72M |
Operating Expenses | 31.78M | 29.83M | 29.67M | 26.97M |
Interest Expense | 1.86M | 1.93M | 1.92M | 1.92M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 165.9M | 153.95M | 148.86M | 144.62M |
Income Tax Expense | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 103.03M | 101.8M | 101.46M | 97.47M |
Shares Outstanding (Diluted) | 103.03M | 101.8M | 101.46M | 97.47M |
EPS (Basic) | -0.08 | -0.02 | -0.06 | -0.14 |
EPS (Diluted) | -0.08 | -0.02 | -0.06 | -0.14 |
EBITDA | -6.09M | 1.06M | -3.96M | -12.86M |
EBIT | -7.93M | -558K | -5.59M | -14.58M |
Depreciation & Amortization | 1.84M | 1.62M | 1.63M | 1.72M |
Add to Watchlist
Select watchlists to add or remove STLN